



24º Congresso Brasileiro de
PERINATOLOGIA

Is It Possible to Prevent Necrotizing Enterocolitis?

Ravi Mangal Patel, MD MSc

Associate Professor of Pediatrics

Emory University School of Medicine, Atlanta, GA, USA



INSTITUTO
PGG

@institutoPGG



EMORY
UNIVERSITY
SCHOOL OF
MEDICINE



Children's™
Healthcare of Atlanta



@ravimpatelmd

Disclosures

I will be discussed the use of probiotics for the prevention of NEC, which is not an approved indication by the US FDA.

I am not endorsing the use of any specific probiotic product.

Instituto PGG



Established in Brazil, in 2016, by a multidisciplinary group, including TV presenter and mother of extreme premature triplets Isabella Fiorentino, to raise awareness of NECROTIZING ENTEROCOLITIS.

- ③ **Free and specialized psychological assistance to family members of affected babies available throughout Brazil.**
- ③ **Creation of a NEC network for the spread of information and connection with foreign specialists and researchers.**
- ③ **Building up of a database with information about NEC in Brazil, open to hospitals and doctors interested in participating.**

Instituto PGG



Close working partnership with:



- We invite you to learn more about our project, join our network and refer affected family members to our psychologists:
contato@pequenosgrandesguerreiros.org
www.pequenosgrandesguerreiros.org
- Join us at the NEC Society 2019 Symposium, 5 - 9 June, Ann Arbor, Michigan, US
www.necsociety.org

Overview

1. Discuss trends in the current incidence of NEC
2. Review risk factors for NEC
3. Highlight potential strategies to prevent NEC

Necrotizing enterocolitis (NEC)


- NEC is multifactorial disease, characterized by intestinal inflammation and necrosis although the exact pathogenesis is not fully elucidated
- Case-fatality rate of 15-30%



Neu and Walker, *NEJM*. 2011
Lin and Stoll, *Lancet*. 2006


Deaths caused by NEC by postnatal age

Causes of death for 6075 deaths among 22,248 live births
at 25 US academic centers within the Neonatal Research Network




Patel RM, et al. *N Engl J Med*. 2015

Trends in incidence of NEC in US



Horbar et al. *JAMA Pediatr.* 2017

Trends in incidence of NEC in US




In 2014, 75% of NICUs achieved NEC rates of the best performing 25% of NICUs in 2005




To prevent NEC, need a framework to address the major causes (*drivers*)

Framework for major drivers of NEC




Drivers of NEC



Feeding approaches and risk of NEC

| Factor | Association with NEC | Observational study | Randomized controlled trial |
|------------------|----------------------|---------------------|-----------------------------|
| Feeding | | | |
| Breast milk | ↓ | X | X |
| Preterm formula | ↑ | X | X |
| Donor human milk | ↓ | X | X |
| Delayed feeding | - | | X |
| Slow feeding | - | | X |
| Trophic feeding | - | | X |
| Feeding protocol | ↓ | X | |

Effect of breastfeeding on NEC



The risk of NEC or death after 14 days was decreased by a factor of 0.83 (95% CI 0.72 - 0.96) for each 10% increase in the proportion of total enteral intake as human milk





Fig. 1. Adjusted survival curves for necrotizing enterocolitis (NEC) or death by proportion of human milk to total intake over the first 14 days of life. Survival

Meinzen-Derr et al. *J Perinatol* 2009



Is donor milk, when mother's milk is not available, a safe and effective intervention to prevent NEC?

Effect of donor milk on NEC (DoMINO trial)

| Outcome | Donor Milk (n=181) | Preterm formula (n=182) | Risk difference (95% CI) |
|----------------------|-----------------------|----------------------------|-----------------------------|
| NEC, Bell stage 2+ | 1.7% | 6.6% | -5% (-9 to -1)* |
| Total weight gain | 1551 g | 1532 g | 30 g (-98 to 158) |
| Mean cognitive score | 93 | 95 | -2 (-6 to 2) |
| Cognitive score <85 | 27% | 16% | 11% (2 to 20)* |

*P <0.05

Effect of donor milk on NEC (DoMINO trial)

| Outcome | Donor Milk (n=181) | Preterm formula (n=182) | Risk difference (95% CI) |
|----------------------|-----------------------|----------------------------|-----------------------------|
| NEC, Bell stage 2+ | 1.7% | 6.6% | -5% (-9 to -1)* |
| Total weight gain | 1551 g | 1532 g | 30 g (-98 to 158) |
| Mean cognitive score | 93 | 95 | -2 (-6 to 2) |
| Cognitive score <85 | 27% | 16% | 11% (2 to 20)* |

*P <0.05

Effect of donor milk on NEC (DoMINO trial)

| Outcome | Donor Milk (n=181) | Preterm formula (n=182) | Risk difference (95% CI) |
|----------------------|-----------------------|----------------------------|-----------------------------|
| NEC, Bell stage 2+ | 1.7% | 6.6% | -5% (-9 to -1)* |
| Total weight gain | 1551 g | 1532 g | 30 g (-98 to 158) |
| Mean cognitive score | 93 | 95 | -2 (-6 to 2) |
| Cognitive score <85 | 27% | 16% | 11% (2 to 20)* |

*P <0.05

Effect of donor milk on NEC (DoMINO trial)


| Outcome | Donor Milk (n=181) | Preterm formula (n=182) | Risk difference (95% CI) |
|----------------------|-----------------------|----------------------------|-----------------------------|
| NEC, Bell stage 2+ | 1.7% | 6.6% | -5% (-9 to -1)* |
| Total weight gain | 1551 g | 1532 g | 30 g (-98 to 158) |
| Mean cognitive score | 93 | 95 | -2 (-6 to 2) |
| Cognitive score <85 | 27% | 16% | 11% (2 to 20)* |

*P <0.05

MILK Trial (NICHD Neonatal Research Network)

- P:** Extremely preterm infants (< 29 wk) whose mothers unable to provide sufficient breastmilk (n=670)
- I:** Donor human milk
- C:** Preterm formula
- O:** neurodevelopment at age 22-26 months of donor human milk as compared to preterm infant formula as the in-hospital diet for infants


Drivers of NEC



Feeding approaches and risk of NEC

| Factor | Association with NEC | Observational study | Randomized controlled trial |
|------------------|----------------------|---------------------|-----------------------------|
| Feeding | | | |
| Breast milk | ↓ | X | X |
| Preterm formula | ↑ | X | X |
| Donor human milk | ↓ | X | X |
| Delayed feeding | - | | X |
| Slow feeding | - | | X |
| Trophic feeding | - | | X |
| Feeding protocol | ↓ | X | |

Standardized feeding associated with less NEC




Standardized feeding protocol associated with lower risk of NEC
 Risk Ratio: 0.22 (95% CI 0.13-0.36) based on 14 studies (n=18,160)

Figure 2. Association of standardized feeding regimen (SFR) and necrotizing enterocolitis (NEC) in preterm neonates.

Effect of slow vs. fast rates of advancement

Incidence of necrotising enterocolitis.




Effect of slow vs. fast rates of advancement

1.1.2 Extremely low birth weight (< 1000 grams) or extremely preterm (< 28 weeks) infants

| | | | | | | | |
|--------------------------|------------|-----|------------|---------------|-------|--------------------------|------|
| Rayyis 1999 | 9 | 43 | 3 | 33 | 4.8% | 2.30 [0.68, 7.84] | 1999 |
| Karagol 2013 | 1 | 14 | 2 | 15 | 2.7% | 0.54 [0.05, 5.28] | 2012 |
| Raban 2014a | 1 | 51 | 7 | 47 | 10.3% | 0.13 [0.02, 1.03] | 2014 |
| Raban 2014b | 9 | 52 | 2 | 50 | 2.9% | 4.33 [0.98, 19.05] | 2014 |
| SIFT 2016 | 53 | 498 | 56 | 496 | 79.3% | 0.94 [0.66, 1.34] | 2016 |
| Subtotal (95% CI) | 658 | | 641 | 100.0% | | 1.01 [0.74, 1.38] | |

Total events 73 70
Heterogeneity: $\text{Chi}^2 = 9.65$, $\text{df} = 4$ ($P = 0.05$); $I^2 = 59\%$
Test for overall effect: $Z = 0.07$ ($P = 0.95$)



1.1.3 Infants small for gestational age or growth restricted


Similar findings among extremely preterm infants (< 28 wk or < 1000 g) and among SGA infants or infants with IUGR

Test for overall effect: $Z = 0.72$ ($P = 0.47$)

1.1.4 Infants with absent or reversed EDFV

| | | | | | | | |
|--------------------------|------------|-----|------------|---------------|-------|--------------------------|------|
| SIFT 2016 | 16 | 226 | 8 | 209 | 80.6% | 1.85 [0.81, 4.23] | 2016 |
| Jain 2016 | 1 | 15 | 2 | 15 | 19.4% | 0.50 [0.05, 4.94] | 2016 |
| Subtotal (95% CI) | 241 | | 224 | 100.0% | | 1.59 [0.74, 3.40] | |

Total events 17 10
Heterogeneity: $\text{Chi}^2 = 1.11$, $\text{df} = 1$ ($P = 0.29$); $I^2 = 10\%$
Test for overall effect: $Z = 1.19$ ($P = 0.23$)



Test for subgroup differences: $\text{Chi}^2 = 1.38$, $\text{df} = 3$ ($P = 0.71$), $I^2 = 0\%$

Oddie et al. *Cochrane Database Syst Rev*. 2017

Is routine monitoring gastric residuals needed?

ORIGINAL
ARTICLES

www.jpeds.com • THE JOURNAL OF PEDIATRICS



The Impact of Routine Evaluation of Gastric Residual Volumes on the Time to Achieve Full Enteral Feeding in Preterm Infants

Arieh Riskin, MD, MHA, Keren Cohen, MD, Amir Kugelman, MD, Arina Toropine, MD, Waseem Said, MD, and David Bader, MD, MHA

Objective evaluation to evaluate **Study design** before (n = **Results** T (P = .02). C from paren (P = .002).

the selective gastric residual volume evaluation group compared with 3.3% in the historic control group (P = .4). Multiple regression analyses showed that the strongest predictor of time to full enteral feedings was GA. Routine evaluation of gastric residual volume and increasing time on noninvasive ventilation both prolonged the attainment of full enteral feedings. Findings were consistent in the subgroup with birth weights of <1500 g. Increased weight at discharge was most strongly associated with advancing postmenstrual age but avoidance of routine evaluations of gastric residual volume also was a significant factor.

Conclusions Avoiding routine evaluation of gastric residual volume before every feeding was associated with earlier attainment of full enteral feedings without increasing risk for NEC. (*J Pediatr* 2017;189:128-34).

THE JOURNAL OF PEDIATRICS • www.jpeds.com



Gastric Residual Volume in Feeding Advancement in Preterm Infants (GRIP Study): A Randomized Trial

Balpreet Singh, MD, MSc^{1,2}, Niels Rochow, MD¹, Lorraine Chessell, RD¹, Jennifer Wilson, MHSc¹, Kathy Cunningham, MHSc¹, Christoph Fusch, MD, PhD^{1,3}, Sourabh Dutta, MD, PhD^{1,4}, and Sumesh Thomas, MD^{1,5}

Although case-control studies suggest residual volumes increase prior to NEC, no studies have shown routine measurement of gastric residuals prevents NEC

residual volume. The primary outcome was the time to reach feeding volumes of 120 mL/kg per day. Secondary outcomes were time to regain BW, episodes of feeding interruptions, sepsis, and necrotizing enterocolitis.

Results Eighty-seven infants were enrolled. There were no differences between the study and control groups with respect to time to reach full feeds (6 days [95% CI, 5.5-6.5] vs 5 days [95% CI, 4.5-5.5]; P = .82), time to regain BW, episodes of feeding interruptions, or sepsis. Two infants in the control group developed necrotizing enterocolitis.

Conclusions Avoiding routine assessment of gastric residual volume before feeding advancement did not shorten the time to reach full feeds in preterm infants with BW between 1500 and 2000 g. (*J Pediatr* 2018;200:79-83).

Trial registration [Clinicaltrials.gov](https://clinicaltrials.gov): NCT01337622.

ORIGINAL
ARTICLES

ing advance-
ent of gastric
rten the time

nts with birth
ngenital mal-
ne was mea-
the control
e gastric re-




INSTITUTO
PGG




Example of feeding protocol at Emory

| Birthweight (kg) | 1.31 | | | | |
|------------------------|------|---------------------|------------------|----------------------|-------------------------------------|
| Day of Enteral Feeding | Date | Goal volume (ml/kg) | Goal volume (ml) | Goal caloric density | Comments |
| 1 | | 20 | 3 | 20 kcal/oz | Trophic feeds (BM preferred) |
| 2 | | 50 | 8 | 20 kcal/oz | Daily advance |
| 3 | | 80 | 13 | 20 kcal/oz | |
| 4 | | 80 | 13 | 22 kcal/oz | If on formula, advance to 24kcal/oz |
| 5 | | 80 | 13 | 24 kcal/oz | |
| 6 | | 110 | 18 | 24 kcal/oz | Discontinue fluids/IV |
| 7 | | 140 | 22 | 24 kcal/oz | |
| 8 | | 150 | 25 | 24 kcal/oz | |


Drivers of NEC




Importance of commensal bacteria



Dysbiosis in NEC




Dysbiosis in NEC




Patel and Denning. *Pediatr Research*. 2015

Dysbiosis before NEC



Warner et al. *Lancet*. 2016



Can probiotics prevent the potential consequences of dysbiosis?

Probiotic: a microorganism (such as lactobacillus) that when consumed (as in a food or a dietary supplement) maintains or restores beneficial bacteria to the digestive tract

[source: Merriam-Webster]


Meta-analyses of probiotics in preterm infants

Summary of recent meta-analyses evaluating treatment effects of probiotics.

| Outcome | Year | Trials, <i>n</i> | Patients, <i>n</i> | RR (95% CI) | <i>I</i> ² | Effects |
|----------------------------------|------|---------------------|-----------------------|------------------|-----------------------|---------|
| NEC (Bell Stage 2 or 3) | | | | | | |
| Sawh et al. ³⁵ | 2016 | 35 | 10520 | 0.53 (0.42–0.66) | 11% | Random |
| Dermyshe et al. ³⁹ | 2017 | 29 | 8535 | 0.57 (0.47–0.70) | 23% | Fixed |
| Chang et al. ⁶² | 2017 | 25 | 7345 | 0.60 (0.48–0.74) | 0% | Fixed |
| Thomas et al. ⁴⁹ | 2017 | 23 | 7325 | 0.57 (0.43–0.74) | 22% | Random |
| Late-onset sepsis | | | | | | |
| Sawh et al. ³⁵ | 2016 | 28 | 8707 | 0.88 (0.77–1.00) | 31% | Random |
| Rao et al. ⁴⁰ | 2016 | 37 | 9416 | 0.86 (0.78–0.94) | 35% | Fixed |
| Dermyshe et al. ³⁹ | 2017 | 28 | 7987 | 0.88 (0.80–0.97) | 17% | Fixed |
| Death | | | | | | |
| Sawh et al. ³⁵ | 2016 | 27 | 9507 | 0.79 (0.68–0.93) | 0% | Random |
| Dermyshe et al. ³⁹ | 2017 | 27 | 8156 | 0.77 (0.65–0.92) | 16% | Fixed |
| Chang et al. ⁶² | 2017 | 21 | 6291 | 0.75 (0.60–0.92) | 9% | Fixed |
| Thomas et al. ⁴⁹ | 2017 | 22 | 6954 | 0.72 (0.57–0.92) | 17% | Random |

Patel and Underwood. *Sem Ped Surg.* 2018


Probiotics and NEC



46 RCTs enrolling 12,185 preterm infants


Risk ratio of effect of probiotics on NEC: 0.5 (95% CI 0.4 - 0.6)

Risk difference: -0.03 (95% CI -0.03 to -0.02)




*unpublished

Cumulative meta-analysis



Patel and Underwood. *Sem Ped Surg.* 2018

Probiotic use in the US



Based on a 2015 survey, 70 (14%) US NICUs were supplementing probiotics in VLBW infants



Probiotics used in:

- 0 NICUs
- 1 to 2 NICUs
- 3 to 4 NICUs
- >4 NICUs

Mostly commonly used probiotics in US

| Probiotic brand | Strains | NICUs using probiotics, n (%) |
|-----------------|--|-------------------------------|
| Culturelle | <i>Lactobacillus rhamnosus</i> GG | 19 (27%) |
| Biogaia | <i>Lactobacillus reuteri</i> | 10 (14%) |
| Gerber Soothe | <i>Lactobacillus reuteri</i> | 10 (14%) |
| Florababy | <i>Bifidobacterium breve, infantis, bifidum, longum, Lactobacillus rhamnosus</i> | 6 (8%) |

Which probiotic do I choose?

Which probiotic product to use remains uncertain, since the total body of evidence comprises a heterogeneous group of probiotics (individual species and combination products, and regimens). In the previous review, only the *Lactobacillus* and multispecies supplements were shown to be effective for this outcome. We would recommend a regulatory body-approved product and that quality assessment be requested from the manufacturer to validate the purity of product. The evidence of benefit was clear for *Lactobacillus* or *Bifidobacterium* species and multiple species products so any of these would be reasonable choices.


Label vs. actual content

Validating bifidobacterial species and subspecies identity in commercial probiotic products

Zachery T. Lewis^{1,2}, Guy Shani^{1,2}, Chad F. Masarweh^{1,2}, Mina Popovic³, Steve A. Frese^{1,2}, David A. Sela⁴, Mark A. Underwood^{2,5} and David A. Mills^{1,2}

- 16 probiotic products containing bifidobacterial species examined using DNA-based methods and confirmed using culture-based techniques.
- “many bifidobacterial probiotic products differ from the ingredient list ... Only 1 of the 16 probiotics perfectly matched its bifidobacterial label claims in all samples tested, and both pill-to-pill and lot-to-lot variation were observed.”

Effectiveness of probiotics in preterm infants




Patel and Underwood. *Sem Ped Surg.* 2018

Routine supplementation of LGG

Table IV. Infant characteristics and outcomes before and after implementation of LGG supplementation

| Characteristics or outcomes | Pre-LGG implementation epoch, 2008-2014 (n = 443) | Post-LGG implementation epoch, 2014-2016 (n = 197) | P* |
|---|---|--|-------|
| Gestational age, wk | 28.7 (26.4-30.6) | 28.3 (26.3-30.6) | .26 |
| Birth weight, g | 1080 (820-1300) | 1000 (740-1270) | .10 |
| Receipt of any initial antibiotics | 366/443 (83%) | 156/197 (79%) | .30 |
| Receipt of prophylactic indomethacin | 164/443 (37%) | 97/197 (49%) | .004 |
| Receipt of any human milk | 387/438 (88%) | 193/197 (98%) | <.001 |
| Age at first feed | 2 (1-3) | 2 (1-3) | .86 |
| Necrotizing enterocolitis stage IIA or greater | 45/443 (10%) | 33/197 (17%) | .02 |
| Necrotizing enterocolitis stage IIIA or IIIB | 20/443 (5%) | 11/197 (6%) | .56 |
| Death | 17/443 (4%) | 13/197 (7%) | .13 |
| Necrotizing enterocolitis (Stage IIA or greater) or death | 53/443 (12%) | 41/197 (21%) | .004 |
| Blood culture-positive sepsis | 86/440 (20%) | 47/196 (24%) | .20 |
| LGG-associated sepsis | 0 (0%) | 0 (0%) | - |

Drivers of NEC



RBC transfusion, anemia and NEC

Original Investigation

Association of Red Blood Cell Transfusion, Anemia, and Necrotizing Enterocolitis in Very Low-Birth-Weight Infants

Ravi M. Patel, MD, MSc; Andrea Knezevic, MS; Neeta Shenvi, MS; Michael Hinkes, MD; Sarah Keene, MD;
John D. Roback, MD, PhD; Kirk A. Easley, MAPStat; Cassandra D. Josephson, MD

Primary objective: To test the hypothesis that the risk of NEC is greater in VLBW infants exposed to RBC transfusion compared to non-transfused VLBW infants

Secondary objective: To determine if exposure to severe anemia (hemoglobin ≤ 8 g/dL) is an independent risk factor for NEC in very low birth weight infants


RBC transfusion not associated with NEC

| Risk Factors | NEC | P Value | % Reliability ^c |
|---|---|---------|----------------------------|
| | Cause-Specific HR (95% CI) ^b | | |
| Model 1—Primary Analysis (N = 598) ^d | | | |
| Birth weight, per 100-g increase | 0.72 (0.62-0.84) | <.001 | 98 |
| Received RBC transfusion in a given week ^e | 0.44 (0.17-1.12) | .09 | 45 |
| Severe anemia in a given week (hemoglobin ≤8 g/dL) ^e | 5.99 (2.00-18.0) | .001 | 70 |
| Days of breast milk feeding in first 10 days of life, per 1-day increase | 1.10 (1.01-1.21) | .04 | 37 |
| SNAP on day of birth, per 1-point increase | 1.00 (0.93-1.07) | .99 | 8 |
| Days of antibiotic treatment in first 10 days of life, per 1-day increase | 1.04 (0.93-1.16) | .50 | 8 |

Severe anemia associated with NEC

| Risk Factors | NEC | P Value | % Reliability ^c |
|---|---|---------|----------------------------|
| | Cause-Specific HR (95% CI) ^b | | |
| Model 1—Primary Analysis (N = 598) ^d | | | |
| Birth weight, per 100-g increase | 0.72 (0.62-0.84) | <.001 | 98 |
| Received RBC transfusion in a given week ^e | 0.44 (0.17-1.12) | .09 | 45 |
| Severe anemia in a given week (hemoglobin ≤8 g/dL) ^e | 5.99 (2.00-18.0) | .001 | 70 |
| Days of breast milk feeding in first 10 days of life, per 1-day increase | 1.10 (1.01-1.21) | .04 | 37 |
| SNAP on day of birth, per 1-point increase | 1.00 (0.93-1.07) | .99 | 8 |
| Days of antibiotic treatment in first 10 days of life, per 1-day increase | 1.04 (0.93-1.16) | .50 | 8 |

Updated meta-analysis of transfusion and NEC



Transfusion of Prematures (TOP) Trial


Enrollment complete (n=1824) and follow-up ongoing

| Table 2 Transfusion of Prematures trial hemoglobin transfusion thresholds | | | | |
|--|--------------------------------|------------|-----------------------------------|------------|
| Time Period | High-Threshold (Liberal) Group | | Low-Threshold (Restrictive) Group | |
| | Respiratory Support | No Support | Respiratory Support | No Support |
| Week 1 | 13.0 | 12.0 | 11.0 | 10.0 |
| Week 2 | 12.5 | 11.0 | 10.0 | 8.5 |
| Weeks ≥ 3 | 11.0 | 10.0 | 8.5 | 7.0 |

Hemoglobin values shown are g/dL. Respiratory support defined as mechanical ventilation, continuous positive airway pressure, fraction of inspired oxygen in excess of 0.35, or oxygen by nasal cannula in excess of 1 L/min.

ClinicalTrials.gov Identifier: NCT01702805

Feeding during RBC transfusion




CONCLUSIONS: Pre-transfusion hematocrit is inversely related to risk of TANEC, which suggests that temporally maintaining a higher baseline hemoglobin in infants most at risk of NEC may be protective. The lack of difference in TANEC pre-/post-implementation of our peri-transfusion feeding protocol, despite an overall temporal decrease in NEC, suggests that other unmeasured interventions may account for the observed decreased incidence of NEC.

FIGURE 2 Association of withholding feeds per transfusion and incidence of transfusion-associated necrotizing enterocolitis in preterm infants. M-H, Mantel-Haenszel.

| Outcome | Absolute risk, n (%) | | Relative effect, RR (95% CI) | Participants, n | GRADE quality of evidence |
|---------|------------------------------------|---|--------------------------------|-----------------|---------------------------|
| | Estimate without withholding feeds | Corresponding estimate with withholding feeds | | | |
| TANEC | 107 of 4534 (2.35) | 22 of 2958 (0.74) | 0.47 (0.28, 0.80), $P = 0.005$ | 7492 | Moderate |

Risk of NEC following transfusion




Feeding during RBC transfusion

<http://neoepoch.com/wheat-trial>



HOME ABOUT US OUR RESEARCH OUR WORK SO FAR GET INVOLVED




Planned enrollment of 4,500 preterm infants

WHEAT TRIAL


WHEAT stands for Withholding Enteral feeds Around packed red cell Transfusion to prevent necrotising enterocolitis in preterm neonates. It is a multi-centre, randomised *point of care trial*. This means that WHEAT uses information that is already being collected by doctors and nurses as part of day to day care, which makes it much simpler and easier to take part in.

Oxygen targeting and risk of NEC


Figure 3. Effect of Oxygen Saturation as Measured by Pulse Oximetry (SpO₂) Target Levels on Secondary Outcomes




Use of near infrared spectroscopy (NIRS)



Drivers of NEC



Effect of quality improvement on NEC



Published quality improvement initiatives involving 378 centers (n=60,485)

Conclusions

- Experience from others centers supports the potential of efforts to prevent NEC
- Breastfeeding is the most important intervention to prevent NEC
- Suggest a long-term timeframe, given NEC is multifactorial and multiple drivers (potential causes) may need to be addressed
- Additional research is necessary to better understand causes of NEC and higher quality evidence to guide prevention efforts

Obrigado !!



@institutoPGG



 @ravimpatelmd

 rmpatel@emory.edu



EMORY
UNIVERSITY
SCHOOL OF
MEDICINE



Children's™
Healthcare of Atlanta



24º Congresso Brasileiro de
PERINATOLOGIA